Results 21 to 30 of about 355,907 (356)

Case Report: Esophagectomy and Azygos Continuation of the Inferior Vena Cava: A Lethal Combination

open access: yesFrontiers in Cardiovascular Medicine, 2022
Azygos continuation of the inferior vena cava (IVC) is rare in the general population and even rarer among patients with esophageal carcinoma. In 90% of cases, this congenital IVC variant is isolated and does not affect the patient’s growth or ...
Yan Zhang   +5 more
doaj   +1 more source

Non-infectious pulmonary complications of hematopoietic stem cell transplantation [PDF]

open access: yes, 2014
Noninfectious pulmonary complications of hematopoietic stem cell transplant are currently more prevalent than infectious complications. Unfortunately, the pathophysiology basis is not completely understood.
Baloglu, Orkun   +2 more
core   +1 more source

Lung transplantation after allogeneic stem cell transplantation : a pan-European experience [PDF]

open access: yes, 2018
Late-onset noninfectious pulmonary complications (LONIPCs) affect 6% of allogeneic stem cell transplantation (SCT) recipients within 5 years, conferring subsequent 5-year survival of 50%.
Aubert, John   +24 more
core   +2 more sources

The Need for Psychological Rehabilitation in Lung Transplant Recipients [PDF]

open access: yes, 2020
Transplant recipients have significant psychosocial stressors due to unique posttransplant sequela that results in an increased incidence of psychopathology.
Chernyak, Yelena, Patel, Anahli
core   +1 more source

Lung transplantation [PDF]

open access: yesF1000Prime Reports, 2013
Lung transplantation may be the only intervention that can prolong survival and improve quality of life for those individuals with advanced lung disease who are acceptable candidates for the procedure. However, these candidates may be extremely ill and require ventilator and/or circulatory support as a bridge to transplantation, and lung ...
openaire   +2 more sources

A prospective randomized trial of fk506 versus cyclosporine after human pulmonary transplantation [PDF]

open access: yes, 1994
We have conducted a unique prospective randomized study to compare the effect of PK506 and cyclosporine (CsA) as the principal immunosuppressive agents after pulmonary transplantation.
Armitage, JM   +11 more
core   +1 more source

Postoperative surgical complications after lung transplantation

open access: yesRevista Portuguesa de Pneumologia (English Edition), 2015
This is a review article on the main postoperative complications after lung transplantation: airways complications, vascular complications, pleural complications, surgical wound complications, and abdominal complications.Incidence data, severity, and ...
M. de la Torre   +6 more
doaj   +1 more source

The XIIIth Banff Conference on Allograft Pathology: The Banff 2015 Heart Meeting Report: Improving Antibody-Mediated Rejection Diagnostics: Strengths, Unmet Needs, and Future Directions. [PDF]

open access: yes, 2017
The 13th Banff Conference on Allograft Pathology was held in Vancouver, British Columbia, Canada from October 5 to 10, 2015. The cardiac session was devoted to current diagnostic issues in heart transplantation with a focus on antibody-mediated rejection
Angelini, A   +18 more
core   +1 more source

Factors influencing transfusion-associated HLA sensitization in patients bridged to heart transplantation using ventricular assist device. [PDF]

open access: yes, 2020
BackgroundBridging heart failure patients with mechanical ventricular assist devices (VAD) enables access to transplantation. However, VAD is associated with increased risk for anti-HLA antibodies associated with rejection of subsequent allografts ...
Adler, Eric   +5 more
core   +1 more source

Primary Erlotinib Resistance in a Patient with Non-Small Cell Lung Cancer Carrying Simultaneous Compound EGFR L718A, Q849H, and L858R Mutations

open access: yesBiomolecular Concepts, 2021
Nowadays, mutations in the epidermal growth factor receptor (EGFR) kinase domain are studied in targeted therapy of non-small cell lung cancer (NSCLC) with EGFR tyrosine kinase inhibitors including gefitinib and erlotinib.
Mirtavoos-mahyari Hanifeh   +6 more
doaj   +1 more source

Home - About - Disclaimer - Privacy